LABT - Latest News
Lakewood-Amedex Biotherapeutics, Inc. (LABT), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $1.1M. Beta to the broader market is -4.76.
The article list below shows the most recent LABT headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent LABT Headlines
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) Stock Short Interest Jumps 146.8%
defenseworld.net - Oct 13, 2026
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT - Get Free Report) was the recipient of a significant increase in short interest in the month of S
Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds
prnewswire.com - Oct 7, 2026
Intravesical administration of the Bisphosphocin ® Nu-8 to rodents infected with E. coli demonstrated up to 97% inhibition of E.
Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences
prnewswire.com - Oct 1, 2026
SARASOTA, Fla. , Oct.
Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers
prnewswire.com - Sep 28, 2026
Lead candidate Nu-3 is a topically formulated Bisphosphocin ® , designed to rapidly kill microbes while reducing the risk of antimicrobial resistance
Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers
prnewswire.com - Sep 24, 2026
Initiation of patient dosing marks significant clinical development milestone for Nu-3 and Lakewood-Amedex Biotherapeutics' proprietary Bisphosphocin
How News Affects LABT Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track LABT's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked LABT news questions
- What is the latest LABT news headline?
- The most recent LABT headline (Oct 13, 2026) is "Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) Stock Short Interest Jumps 146.8%". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the LABT news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What LABT news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual LABT options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.